ジコノチドは重度の慢性疼痛の治療に用いられる
Achim Schmidtko1, Jörn Lötsch, Rainer Freynhagen
1Pharmazentrum Frankfurt/ZAFES, Institut für Klinische Pharmakologie, Goethe-Universität, Frankfurt am Main, Germany.
Lancet (London, England)
|April 24, 2010
まとめ
ジコノチドは,特定のカルシウムチャネルを遮断することによって,重度の慢性疼痛に対する新しいアプローチを提供します. しかし,その狭い治療ウィンドウと副作用により,少数の患者グループでの使用が制限されています.
科学分野:
- 薬理学 薬理学とは
- 神経科学は神経科学である.
- 疼痛管理 疼痛管理
背景:
- 重度の慢性疼痛の管理は,満たされていない重要な治療的ニーズを示します.
- 現在の鎮痛剤は,しばしば耐火性疼痛に十分な緩和を提供できない.
- 静脈内ジコノチドは,このような症例の新たな治療法である.
研究 の 目的:
- 静脈内ジコノチド治療の概要について説明します.
- ジコノチド治療の利点と限界をレビューする.
- N型カルシウムチャネルブロッカーの将来の開発について議論する.
主な方法:
- シコノチドに関する既存の文献のレビュー.
- ジコノチドの薬理学的作用機構の分析.
- 効果と副作用に関する臨床データの評価.
主要な成果:
- ジコノチドは,内経使用に承認された最初の選択的N型電圧感受カルシウムチャネルブロッカーです.
- 脊髄における神経伝達物質の放出を阻害し,痛みを軽減します.
- ジコノチドは,中枢神経系の副作用のために,狭い治療ウィンドウを持っています.
結論:
- 静脈内ジコノチドは,重度,耐火性慢性疼痛に有効です.
- その使用は,副作用のために患者のサブセットに制限されています.
- この薬物クラスに関するさらなる研究は,改善された治療法をもたらす可能性があります.
関連する概念動画
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

